HAVN Life Sciences Inc.
HAVLF · OTC
4/30/2022 | 4/30/2021 | 4/30/2020 | |
|---|---|---|---|
| Revenue | $276 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $187 | $4,605 | $0 |
| Gross Profit | $90 | -$4,605 | $0 |
| % Margin | 32.4% | – | – |
| R&D Expenses | $656 | $333 | $0 |
| G&A Expenses | $8,463 | $19,075 | $41 |
| SG&A Expenses | $8,669 | $19,409 | $41 |
| Sales & Mktg Exp. | $206 | $334 | $0 |
| Other Operating Expenses | $576 | $4,605 | $0 |
| Operating Expenses | $9,900 | $24,346 | $41 |
| Operating Income | -$9,810 | -$30,353 | -$41 |
| % Margin | -3,548.4% | – | – |
| Other Income/Exp. Net | -$12,633 | -$27 | $0 |
| Pre-Tax Income | -$22,444 | -$30,381 | -$41 |
| Tax Expense | $0 | $0 | -$206 |
| Net Income | -$22,444 | -$30,381 | -$41 |
| % Margin | -8,117.8% | – | – |
| EPS | -5.25 | -8.47 | -0.018 |
| % Growth | 38% | -46,438.5% | – |
| EPS Diluted | -5.25 | -8.47 | -0.018 |
| Weighted Avg Shares Out | 4,279 | 3,588 | 2,226 |
| Weighted Avg Shares Out Dil | 4,279 | 3,588 | 2,226 |
| Supplemental Information | – | – | – |
| Interest Income | $30 | $0 | $1 |
| Interest Expense | $64 | $17 | $0 |
| Depreciation & Amortization | $481 | $4,605 | $493 |
| EBITDA | -$7,496 | -$14,845 | $0 |
| % Margin | -2,711.4% | – | – |